艾滋病感染,动物实验 z-bo 2020-10-20 297

　　Two studies, "Science" and "Cell", were published in the United States on the 18th, suggesting that experimental vaccines based on multiple rounds of immunization strategies can inhibit HIV infection. A practical idea of traditional vaccines is to use an inactivated virus to stimulate the body and produce antibodies. However, vaccines developed using "natural" HIV proteins cannot trigger an effective immune response.

　　This is because HIV can evade the immune system and quickly mutate into a new virus strain. The above two studies believe that a successful AIDS vaccine needs to include a series of related but slightly different immunogens. After multiple immunizations, the human body can produce broad-spectrum neutralizing antibodies against HIV. This is different from the traditional "enhanced vaccine" method, in which the vaccinated person will be exposed to the same immunogen multiple times. These two studies are about an immunogen called "eOD-GT860mer".

　　The Scripps Institute and other institutions have tested this, and the results show that it can bind and activate B cells with anti-HIV effects. The two studies used two different mouse models, and the results indicate the hope to develop an effective AIDS vaccine based on this immunogen. "Science" magazine also published the third AIDS study led by Cornell University. Test results of the artificial molecular complex show that this immunogen can stimulate rabbits and monkeys to produce antibodies and prevent them.

　　HIV strain infection. The National Institutes of Health funded these three studies and commented in a statement that these three papers represent "an important new starting point" for AIDS vaccine development.